CG Oncology, Inc. (CGON) stock
CGONNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$84.78+10.38 (+13.95%)
Close on Nov 16, 2026Market cap $7.51BP/E –Yield –
CG Oncology ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
CG Oncology's ebitda for the twelve months ending Sep 30, 2026 was -$261.04M. For fiscal 2025 it was -$189.33M.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$189.33M | – |
| FY2024 | Dec 31, 2024 | -$114.63M | – |
| FY2023 | Dec 31, 2023 | -$55.43M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$62.09M | – |
| Q2 FY2026 | Jun 30, 2026 | -$85.55M | – |
| Q1 FY2026 | Mar 31, 2026 | -$65.55M | – |
| Q4 FY2025 | Dec 31, 2025 | -$47.85M | – |
| Q3 FY2025 | Sep 30, 2025 | -$50.71M | – |
| Q2 FY2025 | Jun 30, 2025 | -$48.59M | – |
| Q1 FY2025 | Mar 31, 2025 | -$42.18M | – |
| Q4 FY2024 | Dec 31, 2024 | -$38.05M | – |
| Q3 FY2024 | Sep 30, 2024 | -$28.27M | – |
| Q2 FY2024 | Jun 30, 2024 | -$25.85M | – |
| Q1 FY2024 | Mar 31, 2024 | -$22.47M | – |
| Q4 FY2023 | Dec 31, 2023 | -$19.35M | – |
| Q3 FY2023 | Sep 30, 2023 | -$14.04M | – |
| Q2 FY2023 | Jun 30, 2023 | -$12.32M | – |
| Q1 FY2023 | Mar 31, 2023 | -$9.72M | – |
See a number that looks wrong?